Sandbox Reserved 1791

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 18: Line 18:
== Antibodies ==
== Antibodies ==
[https://my.clevelandclinic.org/health/body/22971-antibodies Antibodies] are an important part of the thyroid response. These proteins are made in an immune system response to get rid of unwanted antigens in the body. [https://www.btf-thyroid.org/thyroid-antibodies-explained Thyroid antibodies] are made when the body attacks the thyroid tissues. These antibodies are made to mimic [https://my.clevelandclinic.org/health/articles/23524-thyroid-stimulating-hormone-tsh-levels TSH (Thyroid Stimulating Hormone)]. TSH is released from the pituitary gland to bind to TSHR and stimulate the thyroid to make T3 and T4 hormones to regulate the metabolism. These thyroid antibodies bind to the concave surface of the LRD.
[https://my.clevelandclinic.org/health/body/22971-antibodies Antibodies] are an important part of the thyroid response. These proteins are made in an immune system response to get rid of unwanted antigens in the body. [https://www.btf-thyroid.org/thyroid-antibodies-explained Thyroid antibodies] are made when the body attacks the thyroid tissues. These antibodies are made to mimic [https://my.clevelandclinic.org/health/articles/23524-thyroid-stimulating-hormone-tsh-levels TSH (Thyroid Stimulating Hormone)]. TSH is released from the pituitary gland to bind to TSHR and stimulate the thyroid to make T3 and T4 hormones to regulate the metabolism. These thyroid antibodies bind to the concave surface of the LRD.
-
=== M22 ===
+
=== M22 and K1 ===
M22 is an activating antibody for [https://en.wikipedia.org/wiki/Thyrotropin_receptor TSHR]. This antibody mimics [https://my.clevelandclinic.org/health/articles/23524-thyroid-stimulating-hormone-tsh-levels TSH] to activate the thyroid gland to produce [https://www.healthyandnaturalworld.com/t3-t4-thyroid-hormones/ T3 and T4 hormones]. M22 makes a stronger interaction with TSHR than TSH does due to a larger number of hydrogen bonds (14 H bonds for M22 and 3 for TSH) and salt bridge interactions with the concave surface of the LRRD<ref name="M22"> DOI 10.1677/JME-08-0152</ref>. This interaction is key for understanding why M22 activates TSHR and does not release TSHR to go into the inactive state even when T3 and T4 levels are high<ref name="M22"> DOI 10.1677/JME-08-0152</ref>.
M22 is an activating antibody for [https://en.wikipedia.org/wiki/Thyrotropin_receptor TSHR]. This antibody mimics [https://my.clevelandclinic.org/health/articles/23524-thyroid-stimulating-hormone-tsh-levels TSH] to activate the thyroid gland to produce [https://www.healthyandnaturalworld.com/t3-t4-thyroid-hormones/ T3 and T4 hormones]. M22 makes a stronger interaction with TSHR than TSH does due to a larger number of hydrogen bonds (14 H bonds for M22 and 3 for TSH) and salt bridge interactions with the concave surface of the LRRD<ref name="M22"> DOI 10.1677/JME-08-0152</ref>. This interaction is key for understanding why M22 activates TSHR and does not release TSHR to go into the inactive state even when T3 and T4 levels are high<ref name="M22"> DOI 10.1677/JME-08-0152</ref>.
-
=== K1 ===
 
[https://www.creativebiolabs.net/Anti-TSHR-Recombinant-Antibody-clone-K1-70-24911.htm K1] is an inhibitory antibody. This antibody mimics [https://my.clevelandclinic.org/health/articles/23524-thyroid-stimulating-hormone-tsh-levels TSH] and binds to TSHR with a high affinity which prevents the receptor binding to TSH. K1 puts TSHR in the inactive conformation<ref name="K1"> Furmaniak J, Sanders J, Sanders P, Li Y, Rees Smith B. TSH receptor specific monoclonal autoantibody K1-70TM targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy-Results from a phase I clinical trial. Clin Endocrinol (Oxf). 2022 Jun;96(6):878-887. doi: 10.1111/cen.14681. Epub 2022 Feb 6. PMID: 35088429; PMCID: PMC9305464. [DOI 10.1111/cen.14681]</ref>. It is effective at lowering T3 and T4 levels while increasing TSH concentration.
[https://www.creativebiolabs.net/Anti-TSHR-Recombinant-Antibody-clone-K1-70-24911.htm K1] is an inhibitory antibody. This antibody mimics [https://my.clevelandclinic.org/health/articles/23524-thyroid-stimulating-hormone-tsh-levels TSH] and binds to TSHR with a high affinity which prevents the receptor binding to TSH. K1 puts TSHR in the inactive conformation<ref name="K1"> Furmaniak J, Sanders J, Sanders P, Li Y, Rees Smith B. TSH receptor specific monoclonal autoantibody K1-70TM targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy-Results from a phase I clinical trial. Clin Endocrinol (Oxf). 2022 Jun;96(6):878-887. doi: 10.1111/cen.14681. Epub 2022 Feb 6. PMID: 35088429; PMCID: PMC9305464. [DOI 10.1111/cen.14681]</ref>. It is effective at lowering T3 and T4 levels while increasing TSH concentration.
== Active vs. Inactive State ==
== Active vs. Inactive State ==

Revision as of 14:37, 21 April 2023

This Sandbox is Reserved from February 27 through August 31, 2023 for use in the course CH462 Biochemistry II taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1765 through Sandbox Reserved 1795.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Thyroid Stimulating Hormone Receptor (TSHR)

The Human Thyroid Stimulating Hormone Receptor and G-Protein Complex. TSHR is colored based off of its domains. The Leucine Rich Repeat Region (LRRD) is shown in coral. The Hinge Region is shown in bluepurple. The transmembrane region is colored from N to C terminus in a rainbow spectrum. TSH is in navy. And the G-proteins are shown in grey. PDB: 7xw5

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 1.2 1.3 1.4 Faust B, Billesbolle CB, Suomivuori CM, Singh I, Zhang K, Hoppe N, Pinto AFM, Diedrich JK, Muftuoglu Y, Szkudlinski MW, Saghatelian A, Dror RO, Cheng Y, Manglik A. Autoantibody mimicry of hormone action at the thyrotropin receptor. Nature. 2022 Aug 8. pii: 10.1038/s41586-022-05159-1. doi:, 10.1038/s41586-022-05159-1. PMID:35940205 doi:http://dx.doi.org/10.1038/s41586-022-05159-1
  2. 2.0 2.1 2.2 2.3 Duan J, Xu P, Luan X, Ji Y, He X, Song N, Yuan Q, Jin Y, Cheng X, Jiang H, Zheng J, Zhang S, Jiang Y, Xu HE. Hormone- and antibody-mediated activation of the thyrotropin receptor. Nature. 2022 Aug 8. pii: 10.1038/s41586-022-05173-3. doi:, 10.1038/s41586-022-05173-3. PMID:35940204 doi:http://dx.doi.org/10.1038/s41586-022-05173-3
  3. 3.0 3.1 Fokina, E.F., Shpakov, A.O. Thyroid-Stimulating Hormone Receptor: the Role in the Development of Thyroid Pathology and Its Correction. J Evol Biochem Phys 58, 1439–1454 (2022). [DOI:10.1134/S0022093022050143 https://doi.org/10.1134/S0022093022050143]
  4. Chen CR, McLachlan SM, Rapoport B. Thyrotropin (TSH) receptor residue E251 in the extracellular leucine-rich repeat domain is critical for linking TSH binding to receptor activation. Endocrinology. 2010 Apr;151(4):1940-7. doi: 10.1210/en.2009-1430. Epub 2010 Feb 24. PMID: 20181794; PMCID: PMC2851189. [DOI 10.1210/en.2009-1430 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851189/]
  5. 5.0 5.1 Goel R, Raju R, Maharudraiah J, Sameer Kumar GS, Ghosh K, Kumar A, Lakshmi TP, Sharma J, Sharma R, Balakrishnan L, Pan A, Kandasamy K, Christopher R, Krishna V, Mohan SS, Harsha HC, Mathur PP, Pandey A, Keshava Prasad TS. A Signaling Network of Thyroid-Stimulating Hormone. J Proteomics Bioinform. 2011 Oct 29;4:10.4172/jpb.1000195. PMID:24255551 doi:10.4172/jpb.1000195
  6. Maeda S, Koehl A, Matile H, Hu H, Hilger D, Schertler GFX, Manglik A, Skiniotis G, Dawson RJP, Kobilka BK. Development of an antibody fragment that stabilizes GPCR/G-protein complexes. Nat Commun. 2018 Sep 13;9(1):3712. doi: 10.1038/s41467-018-06002-w. PMID:30213947 doi:http://dx.doi.org/10.1038/s41467-018-06002-w
  7. 7.0 7.1 Nunez Miguel R, Sanders J, Chirgadze DY, Furmaniak J, Rees Smith B. Thyroid stimulating autoantibody M22 mimics TSH binding to the TSH receptor leucine rich domain: a comparative structural study of protein-protein interactions. J Mol Endocrinol. 2009 May;42(5):381-95. Epub 2009 Feb 16. PMID:19221175 doi:10.1677/JME-08-0152
  8. Furmaniak J, Sanders J, Sanders P, Li Y, Rees Smith B. TSH receptor specific monoclonal autoantibody K1-70TM targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy-Results from a phase I clinical trial. Clin Endocrinol (Oxf). 2022 Jun;96(6):878-887. doi: 10.1111/cen.14681. Epub 2022 Feb 6. PMID: 35088429; PMCID: PMC9305464. [DOI 10.1111/cen.14681]
  9. Smits G, Govaerts C, Nubourgh I, Pardo L, Vassart G, Costagliola S. Lysine 183 and glutamic acid 157 of the TSH receptor: two interacting residues with a key role in determining specificity toward TSH and human CG. Mol Endocrinol. 2002 Apr;16(4):722-35. doi: 10.1210/mend.16.4.0815. PMID: 11923469. [DOI: 10.1210/mend.16.4.0815 https://pubmed.ncbi.nlm.nih.gov/11923469/]
  10. 10.0 10.1 Chiovato L, Magri F, Carlé A. Hypothyroidism in Context: Where We've Been and Where We're Going. Adv Ther. 2019 Sep;36(Suppl 2):47-58. doi: 10.1007/s12325-019-01080-8. Epub 2019 Sep 4. PMID: 31485975; PMCID: PMC6822815. [DOI: 10.1007/s12325-019-01080-8 https://pubmed.ncbi.nlm.nih.gov/31485975/]
Personal tools